4.6 Article

Current perspectives on wearable rhythm recordings for clinical decision-making: the wEHRAbles 2 survey

期刊

EUROPACE
卷 23, 期 7, 页码 1106-1113

出版社

OXFORD UNIV PRESS
DOI: 10.1093/europace/euab064

关键词

Digital health; Digital medicine; Wearables; Arrhythmia; Atrial fibrillation; Screening; Rhythm monitoring; Telemedicine; EHRA survey

向作者/读者索取更多资源

The survey indicated that wearable single- or multiple-lead ECG technology is widely accepted for screening, diagnostics, monitoring, and follow-up of arrhythmia patients, while there is more reluctance towards using PPG technology for these indications. Most respondents support systematic screening for AF using wearable rhythm devices, but challenges remain in terms of integrating device data into patient files and hospital information systems, as well as reimbursement.
Novel wearable devices for heart rhythm analysis using either photoplethysmography (PPG) or electrocardiogram (ECG) are in daily clinical practice. This survey aimed to assess impact of these technologies on physicians' clinical decision-making and to define, how data from these devices should be presented and integrated into clinical practice. The online survey included 22 questions, focusing on the diagnosis of atrial fibrillation (AF) based on wearable rhythm device recordings, suitable indications for wearable rhythm devices, data presentation and processing, reimbursement, and future perspectives. A total of 539 respondents {median age 38 [interquartile range (IQR) 34-46] years, 29% female} from 51 countries world-wide completed the survey. Whilst most respondents would diagnose AF (83%), fewer would initiate oral anticoagulation therapy based on a single-lead ECG tracing. Significantly fewer still (27%) would make the diagnosis based on PPG-based tracing. Wearable ECG technology is acceptable for the majority of respondents for screening, diagnostics, monitoring, and follow-up of arrhythmia patients, while respondents were more reluctant to use PPG technology for these indications. Most respondents (74%) would advocate systematic screening for AF using wearable rhythm devices, starting at patients' median age of 60 (IQR 50-65) years. Thirty-six percent of respondents stated that there is no reimbursement for diagnostics involving wearable rhythm devices in their countries. Most respondents (56.4%) believe that costs of wearable rhythm devices should be shared between patients and insurances. Wearable single- or multiple-lead ECG technology is accepted for multiple indications in current clinical practice and triggers AF diagnosis and treatment. The unmet needs that call for action are reimbursement plans and integration of wearable rhythm device data into patient's files and hospital information systems. [GRAPHICS] .

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据